Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

Video

In Partnership With:

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3K pathway in patients with metastatic breast cancer.

Although there has not been an agent yet developed that successfully targets PI3K, Chandalapty says the pathway still has a significant role.

PI3K mutations may be less frequent than AKT mutations in patients with metastatic breast cancer, he adds. However, developing a drug that specifically targets PI3K-mutant tumors may help researchers in achieving activity in a difficult-to-treat population.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute